Why Is PEG a Cornerstone Material in Modern Drug Delivery?
PEG is valued in drug delivery because it combines strong hydration, chemical flexibility, broad molecular weight availability, and compatibility with many formulation platforms. These properties allow PEG to function as a solubilizer, stabilizer, spacer, linker, surface coating, and polymeric building block. In practical formulation work, PEG selection often influences not only solubility and stability, but also circulation behavior, biological recognition, and downstream manufacturability.
Chemical Structure and Physicochemical Properties of PEG
PEG is a polyether composed of repeating ethylene oxide units. Its flexible chain structure binds water molecules effectively, forming a hydrated layer around drugs, proteins, particles, or surfaces. This hydration behavior supports compatibility with aqueous buffers, biologics, and colloidal carriers.
Molecular Weight Distribution and Functional Variants
PEG can be selected from short oligomers to high-molecular-weight polymers. Molecular weight affects hydrodynamic size, viscosity, diffusion, renal clearance, and carrier architecture. Careful selection helps balance viscosity, clearance, conjugation efficiency, and final product consistency.
Biocompatibility and Regulatory Acceptance
PEG has a long history of use in pharmaceutical products and biomedical research, although each new PEGylated drug delivery system still requires safety and quality assessment. Material grade, residual impurities, and intended dose should still be evaluated for each formulation.
Water Solubility and Steric Stabilization Effects
PEG's high water solubility helps improve dispersion and formulation stability. PEG chains can also create steric barriers that reduce aggregation and nonspecific interactions. This effect is especially useful for nanoparticles, liposomes , proteins, and poorly soluble payloads.
Understanding the Role of PEG in Drug Delivery Systems
PEG contributes to drug delivery performance through both material-level and biological mechanisms. Before administration, PEG can improve solubilization, dispersion, and storage stability. After administration, PEG may change interactions with proteins, immune cells, tissues, and clearance pathways. These functions make PEG useful across biologics, nanocarriers, polymeric systems, and bioconjugates.
Improving Drug Solubility and Formulation Stability
PEG can improve apparent solubility of hydrophobic drugs and reduce instability in biologic formulations. In polymeric carriers, PEG segments often form hydrophilic shells that maintain dispersion. It also helps maintain uniformity during storage, dilution, and processing.
Extending Circulation Time in the Bloodstream
PEGylation can increase hydrodynamic radius, helping reduce rapid renal clearance. Longer circulation may improve systemic exposure depending on route, dose, payload, and target tissue. This can support less frequent dosing or improved exposure when activity is retained.
Reducing Protein Adsorption and Immune Recognition
PEG-modified surfaces can reduce nonspecific protein adsorption and opsonization, which is important for PEGylated nanoparticles, liposomes, and long-circulating carriers. Optimized PEG coverage can help carriers avoid rapid uptake by clearance systems.
Supporting Controlled and Sustained Drug Release
PEG can be incorporated into hydrogels , block copolymers, micelles, and biodegradable matrices to tune diffusion, degradation, and payload release behavior. The same PEG segment may also improve matrix hydration and payload diffusion control.
What Types of PEG Materials Are Used for Drug Delivery?
PEG materials used in drug delivery differ by architecture, molecular weight, terminal chemistry, purity level, and degradability. Selecting the right PEG material requires matching material structure with payload type, carrier format, conjugation route, and intended biological behavior. The table below summarizes common PEG material categories and their design relevance.
| PEG Material Type | Key Features | Drug Delivery Relevance |
|---|---|---|
| Linear PEG Materials | Predictable chain behavior, broad molecular weight availability, narrow or broad dispersity options, and common terminal modification routes such as methoxy, hydroxyl, amine, carboxyl, NHS ester, and maleimide groups. | Used for drug conjugation, particle coating, linker design, solubility enhancement, protein half-life extension, and surface passivation where a defined single chain architecture is preferred. |
| Branched PEG Materials | Greater steric volume than linear PEG, larger hydrodynamic impact at comparable mass, and architectures such as Y-shaped or multi-branched PEG that can create stronger shielding around payloads. | Selected for stronger steric protection, half-life extension, reduced proteolysis, altered pharmacokinetic behavior, and biologic conjugates where fewer attachment sites are desired. |
| Multi-Arm PEG Materials | Three-, four-, six-, eight-, or higher-arm structures with multiple reactive termini, tunable crosslinking density, and adjustable network mechanics depending on arm number and molecular weight. | Useful for hydrogels, injectable depots, multivalent conjugation, tissue engineering scaffolds, polymer networks, and sustained-release matrices. |
| Heterobifunctional PEG Derivatives | Two different terminal groups for directional conjugation, such as NHS-PEG-maleimide, azide-PEG-amine, alkyne-PEG-biotin, or thiol-PEG-carboxyl derivatives. | Applied in ligand attachment, targeted carriers, antibody modification, protein-drug conjugates, surface functionalization, and sequential coupling workflows. |
| Homobifunctional PEG Derivatives | Identical reactive groups at both chain ends, including diamine, dicarboxyl, di-NHS, di-maleimide, di-azide, and di-alkyne formats for symmetrical reactions. | Used as spacers, crosslinkers, hydrogel precursors, polymer network components, and bifunctional handles for particle or surface modification. |
| Monofunctional PEG Derivatives | Single reactive or capping group for controlled one-point modification, often combined with an inert methoxy terminus to limit uncontrolled crosslinking or multiple substitutions. | Suitable for single-site PEGylation, surface capping, solubility improvement, controlled conjugation, and reducing aggregation without introducing extra reactive ends. |
| PEG-Lipid Materials | PEG attached to lipid anchors such as DSPE, DMG, cholesterol, or other hydrophobic groups, with chain length and anchor stability influencing membrane residence time. | Important in liposomes, lipid nanoparticles , RNA delivery systems, and vesicles to control particle size, colloidal stability, aggregation, circulation time, and formulation reproducibility. |
| PEG-Based Block Copolymers | Amphiphilic structures with hydrophilic PEG segments and hydrophobic blocks such as PLA, PLGA, PCL, poly amino acids, or other biodegradable polymers. | Enable micelles, vesicles, and nanoparticles for poorly soluble drug loading, core-shell design, controlled release, and co-delivery of hydrophobic and hydrophilic payloads. |
Need PEG Materials for Smarter Drug Delivery Design?
Explore suitable PEG linkers, functional PEG derivatives, PEGylation reagents, PEG-lipids, and custom molecular weight options for solubility enhancement, carrier stabilization, controlled release, and bioconjugation workflows.
Carrier Design Principles for PEG-Based Drug Delivery Platforms
PEG-based carrier design requires more than adding a hydrophilic polymer to a formulation. Developers must balance stealth behavior, payload loading, target interaction, manufacturability, and release kinetics to create a delivery system that performs consistently. PEG chain length, surface density, anchoring group, and linker stability should be considered together rather than as isolated variables.
Surface Engineering Strategies
PEG density, chain length, and anchoring group determine surface hydration and steric protection. Dense coatings may reduce protein adsorption, while excessive PEG may limit uptake or ligand binding. An ideal surface design keeps the carrier stable without completely blocking target interaction.
Size and Morphology Optimization
Carrier size influences circulation, tissue penetration, lymphatic transport, and clearance. PEGylated carriers require controlled particle size distribution and morphology for reproducible performance. This is important for consistent biodistribution, filtration behavior, and batch-to-batch performance.
Drug Loading and Encapsulation Considerations
Payload loading depends on polymer-drug compatibility, hydrophobic domains, electrostatic interactions, and formulation process. PEG improves stability but may reduce loading if hydrophilic content is too high. Screening PEG content early helps avoid a trade-off between stability and payload capacity.
Release Kinetics and Stability Design
Release profiles can be controlled through diffusion, linker cleavage, polymer degradation, or environmental triggers. PEGylated carriers must remain stable during storage and circulation while releasing payload at the desired site. Linker choice, polymer composition, and PEG density should therefore be optimized together.
PEGylated Nanocarriers and Their Design Approaches
PEGylated nanocarriers are widely explored because nanoscale platforms can combine payload protection, controlled release, surface modification, and targeting. PEG is commonly used to improve dispersion, reduce aggregation, and adjust biological interactions. In each nanocarrier class, PEG must be optimized together with lipid, polymer, inorganic, or hybrid carrier components.
PEGylated Liposomes
PEGylated liposomes use PEG-lipid conjugates to create hydrated surface layers. They are valuable for improving colloidal stability and prolonging circulation. PEG-lipid type and molar percentage are commonly tuned to balance circulation and release.
Polymeric Nanoparticles with PEG Coatings
Polymeric nanoparticles such as PEG-PLGA or PEG-PLA systems combine biodegradable cores with hydrophilic PEG shells. The core controls drug loading, while the PEG shell improves dispersion and biological interface behavior.
PEG-Modified Micelles
PEG-containing amphiphilic copolymers self-assemble into micelles with hydrophobic cores and PEG coronas. They are often considered for hydrophobic payloads that need aqueous formulation support.
PEGylated Dendrimers
Dendrimers provide multiple surface groups for PEGylation, ligand conjugation, and drug loading. PEG can reduce surface charge effects and improve compatibility with biological environments.
Hybrid and Multifunctional Nanocarriers
Hybrid nanocarriers can integrate polymers, lipids, inorganic cores, imaging agents, ligands, and responsive linkers. PEG provides a flexible interface for combining stability, targeting, and imaging functions.
Inorganic Nanocarriers with PEG Surface Modification
Gold, silica, iron oxide, and other inorganic nanoparticles are often PEGylated to improve dispersion and introduce functional handles. The PEG layer can also provide handles for ligands, dyes, or other functional groups.
How Does PEGylation Improve Drug Delivery Performance?
PEGylation changes the physicochemical and biological profile of drugs and carriers. It may improve stability, solubility, half-life, and biodistribution, but the benefit depends strongly on PEG size, structure, conjugation site, and payload sensitivity. A well-designed PEGylation strategy should preserve therapeutic activity while improving formulation and pharmacokinetic behavior.
Steric Shielding Mechanisms
PEG chains form a flexible hydrated barrier that can protect molecules and carriers from aggregation, enzymatic attack, and nonspecific adsorption. The strength of this shielding depends on PEG chain length, surface density, and architecture.
Reduction of Renal Clearance
Increasing hydrodynamic size through PEGylation can reduce rapid kidney filtration, especially for small proteins, peptides, and fragments. The effect is most useful when the added PEG does not compromise receptor binding or potency.
Improved Biodistribution Profiles
PEGylation can alter how therapeutics distribute across blood, organs, and tissues. This may support better exposure in selected tissues while reducing nonspecific interactions.
Increased Therapeutic Index
By improving exposure and stability, PEGylation may help enhance the balance between efficacy and tolerability. Successful designs improve exposure without adding unacceptable steric hindrance or toxicity burden.
PEGylation Strategies for Different Therapeutic Modalities
Different therapeutic modalities require different PEGylation strategies. Small molecules may need cleavable PEG prodrug linkers, while proteins often require site-specific conjugation that preserves activity. Nucleic acids and nanoparticles may rely on PEG-containing lipids or polymers to control formulation performance, particle stability, and delivery efficiency.
PEGylation of Small-Molecule Drugs
Small-molecule PEGylation can improve solubility and modify distribution. Cleavable linkers are often considered when release of the parent compound is required. Spacer length and linker stability should match the desired release mechanism.
PEGylation of Peptides
Peptides benefit from PEGylation when enzymatic degradation and rapid clearance limit exposure. Site and molecular weight selection are critical for maintaining receptor interaction.
PEGylation of Proteins
Protein PEGylation may improve stability and half-life. Site-specific approaches help preserve activity and consistency. Analytical control is especially important because heterogeneous conjugates can behave differently.
PEGylation of Enzymes
Enzyme PEGylation can reduce degradation and alter immunological exposure while preserving catalytic activity. Conjugation conditions should protect active sites and avoid excessive structural disruption.
PEGylation of Cytokines and Growth Factors
PEGylation can extend exposure but must avoid receptor-binding domains. Site-aware designs help retain signaling activity while improving exposure.
PEGylation of Antibodies
Antibodies and antibody fragments may use PEGylation to adjust size, circulation, and distribution. This is particularly relevant for fragments or formats with shorter native half-life.
PEGylation of Oligonucleotides
PEGylated oligonucleotides may show improved nuclease resistance and formulation behavior. PEG can also help tune hydrodynamic size and carrier compatibility.
PEGylation of siRNA and mRNA Therapeutics
PEG lipids and PEGylated polymers help control RNA nanoparticle size and stability. PEG amount often needs careful adjustment to avoid reduced cell uptake.
PEGylation of Nanomedicine Platforms
Nanomedicine platforms use PEG as a stealth coating, linker, or stabilizer. It can also act as a spacer for ligands or responsive linkers.
Common PEGylation Chemistries and Conjugation Techniques
PEGylation chemistry determines conjugation selectivity, stability, product heterogeneity, and biological performance. Selection should account for available functional groups, payload sensitivity, desired linker stability, purification complexity, and analytical requirements. The table below summarizes common PEGylation chemistries and their typical use cases.
| PEGylation Chemistry | Reaction Focus | Typical Use Cases |
|---|---|---|
| Amine-Reactive PEGylation | Targets lysine residues or N-terminal amines, commonly using NHS ester PEG , activated carbonate PEG, isocyanate PEG, or related amine-reactive reagents under controlled pH conditions. | Protein modification, peptide PEGylation, formulation screening, and early conjugation programs where multiple accessible amines can be tolerated or later purified. |
| Thiol-Reactive PEGylation | Targets cysteine residues, often using maleimide PEG , vinyl sulfone PEG, iodoacetamide PEG, or pyridyl disulfide PEG to improve site direction through engineered or native thiols. | Site-directed protein modification, antibody fragment conjugation, peptide modification, nanoparticle surface functionalization, and ligand installation on thiolated surfaces. |
| Carboxyl-Reactive PEGylation | Uses carboxyl-containing drugs, polymers, peptides, or proteins with carbodiimide or activated ester coupling chemistry that requires control of pH, buffer, and competing nucleophiles. | Polymer conjugation, small-molecule modification, peptide coupling, surface activation, and selected bioconjugation workflows where carboxyl groups are the preferred handle. |
| Aldehyde and Ketone Chemistry | Enables oxime ligation, hydrazone formation, or reductive amination through carbonyl groups, including oxidized glycans or engineered aldehyde tags. | Site-selective conjugation when defined carbonyl handles are introduced, glycoprotein modification, releasable linker design, and biologic PEGylation with improved positional control. |
| Click Chemistry-Based PEGylation | Uses azide-alkyne cycloaddition, strain-promoted click reactions, tetrazine ligation, or related bioorthogonal reactions for efficient and selective bond formation. | Bioconjugation, linker construction, surface engineering, imaging probe attachment, ligand installation, and multifunctional carrier design with orthogonal reaction pairs. |
| Enzymatic PEGylation | Uses enzyme-recognized motifs, glycans, peptide sequences, or transpeptidation handles to improve site specificity and reduce random modification. | Biologic conjugation where reduced heterogeneity and defined modification sites are desired, including glycoPEGylation, sortase-mediated conjugation, and transglutaminase-compatible systems. |
| Photochemical PEGylation | Uses light-activated groups such as photo-crosslinkers, thiol-ene systems, or photo-triggered reactions to initiate spatially or temporally controlled PEG attachment. | Hydrogel fabrication, surface patterning, cell-compatible matrix modification, localized PEG installation, and controlled network formation. |
| Cleavable PEG Linker Strategies | Uses pH-, enzyme-, redox-, ester-, disulfide-, carbonate-, hydrazone-, or hydrolysis-sensitive linkers designed to separate PEG from payload or carrier under defined conditions. | Responsive delivery, prodrug design, PEG shedding, controlled payload release, intracellular delivery concepts, and systems that need long circulation followed by active uptake. |
| Reversible PEGylation | Provides temporary PEG shielding during circulation and allows later de-shielding or release through labile linkers, exchangeable anchors, or environment-sensitive bonds. | Systems designed to balance long circulation with target-cell uptake, endosomal release, intracellular delivery, and recovery of parent drug or biologic activity. |
| Surface-Initiated or Grafting PEGylation | Attaches PEG chains to particles, membranes, devices, or polymer surfaces by grafting-to or grafting-from approaches, with density controlled by surface chemistry and process conditions. | Nanoparticle coating, implant surface modification, biosensor passivation, liposome stabilization, and reduction of nonspecific adsorption on delivery interfaces. |
Find the Right PEG Drug Delivery Guide for Your Project
Use these focused guides to move from broad PEG concepts to practical material selection. Whether you are comparing PEG molecular weight, selecting reactive end groups, designing PEGylated carriers, or troubleshooting PEGylation workflows, each page helps you quickly find the most relevant next step for your formulation or conjugation project.
How Does Molecular Weight Influence PEG Drug Delivery Systems?
PEG molecular weight is one of the most important design variables in PEG drug delivery. It influences hydrodynamic size, circulation half-life, tissue penetration, solubility, viscosity, drug loading, and clearance. The ideal molecular weight is application-specific and should be evaluated together with payload size, administration route, carrier structure, and expected dosing frequency.
Impact on Circulation Half-Life
Higher molecular weight PEG can increase hydrodynamic size and reduce rapid clearance. However, very large PEG chains may also change tissue penetration and clearance routes.
Impact on Biodistribution and Tissue Penetration
Smaller PEG chains may allow better diffusion, while larger chains can improve circulation stability. The selected range should reflect the target tissue, route of administration, and payload size.
Impact on Drug Loading Capacity
PEG content can influence carrier core-shell balance and hydrophobic drug loading. Optimizing the hydrophilic-hydrophobic balance helps maintain both loading and colloidal stability.
Impact on Clearance Pathways
PEG architecture and size influence renal, hepatic, and macrophage-mediated clearance. These pathways should be considered with total PEG dose and repeat-administration plans.
Challenges and Limitations of PEG-Based Drug Delivery
Although PEG is highly useful, PEGylated systems also face challenges. These include anti-PEG immune responses, accelerated clearance, reduced cellular uptake, manufacturing complexity, and evolving regulatory expectations. Addressing these issues requires early material screening, careful PEG density optimization, robust analytical methods, and a clear understanding of the intended clinical or research context.
Accelerated Blood Clearance Phenomenon
Repeated dosing of some PEGylated systems may cause faster clearance, depending on formulation, dose, interval, and immune response. Early repeat-dose assessment can help identify whether PEG density, dose interval, or carrier composition needs adjustment.
Anti-PEG Antibody Formation
Anti-PEG antibodies may affect pharmacokinetics or tolerability in certain systems. Risk evaluation should consider patient exposure history, product format, and intended dosing frequency.
Reduced Cellular Uptake
Dense PEG coatings can improve stealth behavior but may also reduce cell binding and internalization. Designs may use ligand display, cleavable PEG, or lower PEG density to recover uptake at the target site.
Manufacturing and Scale-Up Challenges
PEGylated products require control over conjugation ratio, purity, residual reagents, dispersity, and batch consistency. Robust process controls are needed to maintain comparable material attributes from screening to larger batches.
Long-Term Safety Considerations
Safety evaluation should consider PEG molecular weight, dose burden, degradation behavior, tissue distribution, and immune response. Developers should assess accumulation potential, excretion, and formulation-specific immune signals.
Regulatory Uncertainty Around Immunogenicity
Regulatory expectations continue to evolve as PEGylated therapeutics and nanomedicines become more complex. Clear characterization and justified control strategies can reduce uncertainty during development planning.
Pharmaceutical Development and Manufacturing Considerations
Translating PEG-based drug delivery systems from concept to development requires strong analytical control. Material identity, purity, functionalization level, residual impurities, formulation stability, and process reproducibility must be considered early. For PEGylated therapeutics, small differences in PEG material quality or conjugation efficiency can influence product consistency and biological performance.
PEG Material Selection Criteria
Key factors include molecular weight, architecture, end-group chemistry, purity, dispersity, solubility, linker stability, and compatibility. A well-defined specification reduces variability before conjugation or formulation development begins.
Formulation Development Requirements
PEG-containing formulations should be evaluated for particle size, zeta potential, pH, osmolality, buffer compatibility, storage stability, and release performance. These attributes should be monitored after processing, storage, dilution, and stress conditions.
Process Development and Scale-Up
Scale-up requires reproducible reactions, purification methods, solvent control, impurity profiling, and analytical criteria. Early selection of scalable chemistry can prevent late-stage reformulation or purification issues.
Quality Control and Characterization Methods
Common methods include SEC, HPLC, NMR, MALDI-TOF, LC-MS, DLS, zeta potential analysis, endotoxin testing, and functional group quantification. Combining orthogonal methods improves confidence in identity, purity, conjugation ratio, and particle behavior.
PEG Applications Across Major Therapeutic Areas
PEG materials are used across a wide range of therapeutic areas because they can support multiple drug formats, including small molecules, proteins, peptides, nucleic acids, vaccines, hydrogels, and nanoparticles. Application-specific PEG design depends on route of administration, therapeutic window, payload stability, tissue distribution, release requirements, and manufacturing constraints.
Oncology Drug Delivery
PEGylated liposomes, micelles, nanoparticles, and prodrugs are widely studied for anticancer payload stabilization and controlled delivery. PEG choice can influence circulation, tumor exposure, and tolerability of carrier-based formulations.
Vaccine and Immunotherapy Delivery
PEG-containing lipid and polymer systems may improve formulation stability and delivery behavior in vaccine and immunotherapy applications. PEG level should be tuned so stability benefits do not unnecessarily limit immune-cell interaction.
Gene and RNA-Based Therapeutics
PEG lipids and PEGylated polymers help regulate RNA nanoparticle size, aggregation, and manufacturing consistency. It is especially important for lipid nanoparticles and polymer systems that require tight size control.
Protein and Peptide Therapeutics
PEGylated proteins and peptides can show improved stability and longer circulation when conjugation preserves activity. The goal is to extend exposure while preserving binding, folding, and biological function.
Rare Disease Treatments
Enzyme and biologic therapies for rare diseases may use PEGylation to improve exposure and reduce rapid clearance. Longer exposure may be valuable for chronic dosing schedules when safety is well controlled.
Inflammatory and Autoimmune Disorders
PEGylated biologics and carriers can help modify pharmacokinetics in repeated-dose inflammatory and autoimmune applications. Consistent PEGylation can help maintain predictable exposure across repeated dosing regimens.
How Can BOC Sciences' PEG Supply Capabilities Support Drug Delivery Needs?
BOC Sciences supports PEG-related drug delivery research by providing PEG materials, functional PEG derivatives, PEG linkers, PEGylation reagents, and custom PEG synthesis services. These capabilities can support early research, formulation screening, bioconjugation development, nanomedicine design, and scale-up preparation.
PEG Material Supply
BOC Sciences can support researchers with different PEG material formats for carrier design and formulation screening.
- Linear, branched, and multi-arm PEG
- PEG copolymers and PEG-lipid materials
- Different molecular weight ranges
- Research-scale and development-scale supply
Functional PEG Derivatives
Functional PEG derivatives are available for diverse conjugation and surface modification workflows.
- Amine, carboxyl, thiol, and aldehyde PEG
- NHS ester, maleimide, azide, and alkyne PEG
- Biotin, fluorescent, and specialty PEG derivatives
- Mono-, homo-, and heterobifunctional PEG options
PEG Linkers and Spacers
PEG linkers can help connect payloads, ligands, proteins, surfaces, and nanoparticles while improving solubility and spatial flexibility.
- Cleavable and non-cleavable PEG linkers
- Short and long PEG spacer designs
- Linkers for targeting ligand conjugation
- Bioconjugation and surface engineering support
Custom PEG Synthesis
Custom synthesis can address project-specific PEG structures when catalog materials do not meet application needs.
- Defined molecular weight targets
- Terminal group customization
- Multi-arm and branched PEG structures
- Custom cleavable or responsive PEG designs
PEGylation Reagent Support
PEGylation reagents can support biologic modification, nanocarrier construction, and formulation development.
- Protein, peptide, and enzyme PEGylation
- Antibody fragment conjugation
- Oligonucleotide and RNA delivery research
- Nanoparticle coating and hydrogel construction
Analytical and Quality Support
BOC Sciences can provide material information and characterization support according to project requirements.
- Identity and purity information
- Molecular weight and dispersity support
- Functional group conversion data
- Batch consistency and documentation support
Discuss PEG Materials, Linkers, or Custom Synthesis Needs
Share your target PEG architecture, molecular weight, terminal groups, quantity, purity expectations, and application scenario. BOC Sciences can help match catalog PEG materials or develop customized derivatives for drug delivery research and formulation screening.
Frequently Asked Questions
Explore answers to the most common questions researchers and formulation developers have when selecting PEG materials, designing PEGylation strategies, and evaluating drug delivery systems.
What makes PEG useful in drug delivery?
How is PEG molecular weight selected?
What PEG reagents are commonly used for PEGylation?
Why can PEGylation reduce cellular uptake?
Can PEG be used in RNA delivery systems?
How can BOC Sciences support PEG drug delivery projects?
Request PEG Materials or Custom PEG Synthesis Support
Share PEG material specifications, target molecular weight, functional groups, application area, and quantity requirements. BOC Sciences can help evaluate suitable PEG materials or customization options for drug delivery research.
